STAT Plus: Safety concerns regarding Novartis’s new eye drug boost Regeneron stock
A leading association of eye doctors has warned its members about safety concerns about Novartis’s new eye drug, sending the company’s stock down sharply Monday while that of Regeneron Pharmaceuticals, which produces a competing product, rose.
The American Society of Retina Specialists sent its membership an email about the drug, Beovu, on Sunday, warning that some doctors were reporting not just a known side effect, eye inflammation, but also a new one, vasculitis.
Continue to STAT Plus to read the full story…
